LONDON, July 30 (Reuters) - British drugmaker GSK

said on Wednesday it is in talks with the Trump

administration about ways to lower U.S. drug costs, becoming the

latest pharmaceutical company to acknowledge action under

pressure from Washington to rein in prices.

GSK CEO Emma Walmsley said on a call with journalists after

the company posted second-quarter profits above analyst

expectations that the discussions with the U.S. administration

are "about how to make sure discounts are passed on to patients

and pricing is sustainable, both for the government and also for

industry."